The risk of idiopathic thrombocytopenic purpura after first and second measles, mumps, rubella (MMR) vaccine doses in children born in England 2000-2019.
پخش حرفهای فارسی و انگلیسی
در حال بررسی نسخههای صوتی ذخیرهشده…
تنظیم صدای طبیعی و سرعت
صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده میشود معمولاً طبیعیترند. انتخاب صدا به صداهای نصبشده در ویندوز و مرورگر شما بستگی دارد.
چکیده اصلی
We assessed the risk of Idiopathic thrombocytopenic purpura (ITP) after Measles Mumps Rubella vaccine (MMR) doses 1 and 2 in children in England born from 2000 to 2019. After linking hospitalised ITP episodes to MMR vaccine records, we used the self-control case-series method to assess the relative incidence in the 6-week period post vaccination. We also assessed the risk of ITP after dose 2 in those who had ITP after dose 1. We found an increased risk of ITP after dose 1 (relative incidence 2.38 (95% CI: 2.12-2.67)) with an attributable risk of 1 in 42,900 doses. We found no evidence of an increased risk after dose 2 (relative incidence 0.96 (95% CI: 0.81-1.13)). Furthermore, we found that the 336 children with ITP after dose 1 who had MMR dose 2 had no increased risk in the 6-weeks after this dose and that it is therefore safe to vaccinate these children.
متن کامل اصلی
برای بررسی دسترسی کتابخانهای یا خرید، رکورد اصلی را باز کنید.
رفتن به منبع اصلی